Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical

Growth Stage

Aiming to Impact Billions of Lives by Changing the Way the World Treats Inflammation

Aiming to Impact Billions of Lives by Changing the Way the World Treats Inflammation

Overview

Raised to Date: Raised: $1,241,077

Total Commitments ($USD)

Platform

Wefunder

Start Date

06/01/2023

Close Date

09/15/2024

Min. Goal
$150,000
Max. Goal
$3,000,000
Min. Investment

$250

Security Type

Convertible Note

Series

Series A

SEC Filing Type

RegCF    Open SEC Filing

Early Bird Val. Cap

$70,000,000

Valuation Cap

$80,000,000

Discount

20%

Rolling Commitments ($USD)

Status

Active

Reporting Date

05/17/2024

Days Remaining

120

% of Min. Goal

827%

% of Max. Goal

41%

Likelihood of Max
unlikely
Avg. Daily Raise

$3,536

# of Investors

476

Momentum
cool.svg
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2017

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2C

Margin

Medium

Capital Intensity

Low

Location

Huntington, New York

Business Type

Growth

Sen-Jam Pharmaceutical, with a valuation of $80 million, is raising funds on Wefunder. The pharmaceutical company makes highly accessible, safe, and affordable drugs that work. The drugs of Sen-Jam Pharmaceutical combine NSAIDs and antihistamines to prevent inflammation and associated pain. Sen-Jam Pharmaceutical is majorly targeting opioid withdrawal, alcohol hangover prevention, and COVID-19 therapeutic. The company has a strong global IP portfolio with 40 patents and world-class partners. Jim Iversen and Jackie Iversen founded Sen-Jam Pharmaceutical in August 2017. The current crowdfunding campaign has a minimum target of $150,000 and a maximum target of $3 million. The campaign proceeds will be used for product development, regulatory affairs, marketing, communications, intellectual property advancement, and operating expenses.

Summary Profit and Loss Statement

FY 2023 FY 2022

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-4,355,706

$-3,983,709

Summary Balance Sheet

FY 2023 FY 2022

Cash

$331,764

$181,148

Accounts Receivable

$0

$0

Total Assets

$950,081

$663,018

Short-Term Debt

$1,111,512

$1,992,097

Long-Term Debt

$1,756,114

$170,896

Total Liabilities

$2,867,626

$2,162,993

Financials as of: 06/01/2023
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Sen-Jam Pharmaceutical 09/14/2024 Wefunder $80,000,000 $1,241,077 Convertible Note Active RegCF
Sen-Jam Pharmaceutical 01/05/2024 Self Managed - - Convertible Note Funded RegD 506(c)
Sen-Jam Pharmaceutical 01/10/2023 StartEngine $69,979,019 $312,093 Equity - Common Funded RegCF
Sen-Jam Pharmaceutical 07/30/2022 Wefunder $25,000,000 $1,008,951 Convertible Note Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Founder Profile

Sen-Jam: Pioneering Anti-Inflammatory Solutions

In a relentless pursuit to revolutionize the treatment of inflammation, Sen-Jam Pharmaceutical is emerging as a formidable player in the biotech industry. Co-founder and Chief Clinical Officer Jacqueline Iversen brings a unique perspective, blending her extensive pharmaceutical knowledge with a patient-first approach. Sen-Jam stands out in the $217 billion market with its groundbreaking solutions for acute and chronic inflammation, impacting areas as diverse as hangovers, opioid withdrawal, and upper respiratory infections. We caught up with Iverson to learn about her deep-rooted passion for holistic pharmacy and vision for addressing systemic inflammation.


Read Founder Interview

Add to portfolio
Sen-Jam Pharmaceutical on Wefunder 2023
Platform: Wefunder
Security Type: Convertible Note
Valuation: $80,000,000

Follow company

Follow Sen-Jam Pharmaceutical on Wefunder 2023

Buy Sen-Jam Pharmaceutical's Deal Report

Sen-Jam Pharmaceutical Deal Report

Get KingsCrowd’s comprehensive report on Sen-Jam Pharmaceutical including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Sen-Jam Pharmaceutical is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Sen-Jam Pharmaceutical deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge